A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation

This publication has 19 references indexed in Scilit:

• Amifostine as mucosal protectant in patients with locally advanced non-small cell lung cancer (NSCLC) receiving intensive chemotherapy and thoracic radiotherapy (RT): results of the radiation therapy oncology group (RTOG) 98–01 study
  International Journal of Radiation Oncology*Biology*Physics, 2003
• Does amifostine have a role in chemoradiation treatment?
  The Lancet Oncology, 2003
• Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity
  Seminars in Oncology, 2002
• Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma
  Bone Marrow Transplantation, 2002
• A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation*
  British Journal of Cancer, 2001
• Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation
  Bone Marrow Transplantation, 2000
• Amifostine (WR-2721) Protects Normal Haematopoietic Stem Cells Against Cyclophosphamide Derivatives' Toxicity Without Compromising Their Antileukaemic Effects
  European Journal Of Cancer, 1995
• Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
  New England Journal of Medicine, 1986
• Reporting results of cancer treatment
  Cancer, 1981
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958